



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

The Multi-faceted role of GATA3 in developmental haematopoiesis

Citation for published version:

Zaidan, N & Ottersbach, K 2018, 'The Multi-faceted role of GATA3 in developmental haematopoiesis', *Open Biology*. <https://doi.org/10.1098/rsob.180152>

Digital Object Identifier (DOI):

[10.1098/rsob.180152](https://doi.org/10.1098/rsob.180152)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Open Biology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Cite this article: Zaidan N, Ottersbach K. 2018 The multi-faceted role of Gata3 in developmental haematopoiesis. *Open Biol.* **8:** 180152. <http://dx.doi.org/10.1098/rsob.180152>

Received: 28 August 2018
Accepted: 29 October 2018

Subject Area:
developmental biology

Keywords:
Gata3, haematopoiesis, development

Author for correspondence:
Katrin Ottersbach
e-mail: katrin.ottersbach@ed.ac.uk

The multi-faceted role of Gata3 in developmental haematopoiesis

Nada Zaidan^{1,2} and Katrin Ottersbach¹

¹MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK

²King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia

KO, 0000-0002-6880-4895

The transcription factor Gata3 is crucial for the development of several tissues and cell lineages both during development as well as postnatally. This importance is apparent from the early embryonic lethality following germline Gata3 deletion, with embryos displaying a number of phenotypes, and from the fact that Gata3 has been implicated in several cancer types. It often acts at the level of stem and progenitor cells in which it controls the expression of key lineage-determining factors as well as cell cycle genes, thus being one of the main drivers of cell fate choice and tissue morphogenesis. Gata3 is involved at various stages of haematopoiesis both in the adult as well as during development. This review summarizes the various contributions of Gata3 to haematopoiesis with a particular focus on the emergence of the first haematopoietic stem cells in the embryo—a process that appears to be influenced by Gata3 at various levels, thus highlighting the complex nature of Gata3 action.

1. Introduction

Haematopoiesis refers to the formation of blood cellular components. All these components originate from multipotent haematopoietic stem cells (HSCs), which form the foundation of this process. The system is traditionally seen as hierarchical, with the multipotent HSC being the mother cell that gives rise to and differentiates into multipotent and unipotent intermediate progenitor cells, resulting in the production of functional mature blood cells, although in recent years exceptions have been discovered that have an HSC-independent origin (reviewed in [1]). As such, HSCs have unique characteristics that in combination distinguish them from other more mature cells: (i) self-renewal ability; (ii) high proliferation ability; (iii) long-term activity; and (iv) potential to differentiate into all the different haematopoietic lineages. All these characteristics make those cells the most clinically relevant cells for transplants.

Haematopoiesis is a complex and intricate process that is governed by a large number of signalling pathways and transcription factors. The transcription factors themselves are often organized in multi-gene families and play essential roles in activating target genes of specific cell fates and in repressing target genes of alternative cell fates. The GATA family of transcription factors are such master regulators. This family has six members in vertebrates, and the disruption of each of the *Gata* genes, with exception of *Gata5*, causes embryonic lethality in mice. They are grouped into haematopoietic (*Gata1*, *Gata2*, *Gata3*), and endodermal (*Gata4*, *Gata5*, *Gata6*) subgroups (recently reviewed in [2]). Each GATA transcription factor is highly conserved across vertebrates. For example, *Gata3* homologues are found in human, mouse, rat, chimpanzee, dog, chicken, frog and zebrafish. *Gata3* shares 97% of its amino acid identity between mouse and human. Within the GATA family, members share varying degrees of homology. For example, while GATA2 and GATA3 are about 55% homologous at the amino acid level, GATA3 and GATA4 are only 20% homologous.

The largest degree of conservation is found in the zinc finger domains, which are about 80% homologous among all six members. The two zinc fingers bind to different sequences and each has a unique function. The C-finger binds to the GATA consensus site, WGATAR, although in a genome-wide ChIP-seq experiment, Fujiwara *et al.* [3] reported that GATA proteins preferred binding to WGATAA sequences *in vivo*. However, the abundance of these motifs is such that the binding of GATA factors to specific DNA loci cannot be inferred from the presence of the sequence alone. Instead, it has become clear that occupancy of specific DNA sites by GATA factors is dependent on the presence of other co-regulatory proteins which can facilitate recruitment of GATA factors to specific protein complexes or regulate GATA activity through post-translational modifications (reviewed in [4]).

The N-finger facilitates the interaction with such co-regulatory proteins, but can also bind specific, yet distinct, DNA sequences [3,5–7]. This combination of DNA sequence-specific binding and recruitment to chromatin via a dynamic range of protein complexes resulting in both transcriptional activation and repression allows GATA factors to participate in a large repertoire of different processes that are highly cell context-dependent. In the case of Gata3, this has been extensively studied in lymphoid development, regulated by Gata3 at various stages, which has recently been comprehensively reviewed [8]. In addition, in a crystallographic structural study by Bates *et al.* [9] for Gata3, it was observed that GATA family members could bind to DNA by either homo- or heterodimerizing, by forming a dimer with other GATA factors through their two C-fingers.

All GATA factors have both distinct and common biological roles and biochemical characteristics, and all have a restricted expression pattern, which is controlled by tissue-specific enhancer elements. The regulatory elements that control Gata3 expression have been well characterized through the identification of enhancers that drive its expression in the urogenital system, the central nervous system, the endocardium and in natural killer (NK)/T-cells, with the NK/T-cell-specific element being located 280 kb downstream of the *Gata3* gene [10,11]. However, in some cases, the functions of GATA factors are interchangeable [12]. For example, Gata1, Gata2, Gata3 and Gata4 can activate interleukin-4 (Il4) and Il5 expression in T-cells, which are classically target genes for Gata3, and repress the activation of interferon- γ [13]. Moreover, a *Gata3* knock-in can partially rescue erythrocyte defects in *Gata1* null mice; however, Gata3 cannot fully rescue the phenotype of *Gata1* null mice, indicating that each GATA factor maintains its unique functions [14,15].

2. The three haematopoietic GATAs

While Gata4, Gata5 and Gata6 drive differentiation of mesoderm- and endoderm-derived tissues and are therefore critical for the development of heart and lung, the first three members of the GATA family are involved in the differentiation of mesoderm- and ectoderm-derived tissues and play essential roles in the development and maintenance of the haematopoietic system. Very broadly speaking, the main function of Gata1 is cell fate determination at an early branch point in the haematopoietic tree, where it induces megakaryocyte and erythrocyte development, while preventing granulocyte-monocyte and lymphoid commitment. However, it is also

expressed further downstream in common lymphoid and myeloid progenitors, mast cells and eosinophils [16,17]. The most critical role of Gata2 is the formation and maintenance of HSCs [18,19], although it has additional functions in specific blood lineages as discussed below. Gata3 is crucial for the development of several lymphoid lineages (reviewed in [8]) and early definite haematopoietic stem and progenitor cells [20,21], which will be discussed further below.

The haematopoietic group within the GATA factors control each other's expression during development in different cells, and are capable of functioning consecutively during cell specification and lineage commitment in a process called a GATA switch. GATA switch refers to instances where one GATA factor is replaced by another GATA at the chromatin site. GATA switches occur at many functionally critical loci during development, including those that control the expression of regulators of haematopoiesis, such as Gata2 itself [22]. Gata2 is a direct target of Gata1; however, in the absence of Gata1, it can bind to a target region upstream of its own promoter, which activates transcription and induces histone acetylation. However, when Gata1 is expressed, Gata2 is displaced by Gata1 at its chromatin site, which activates erythropoiesis [23,24] (and reviewed in [4,22]).

2.1. Gata1

The essential role of Gata1 in erythropoiesis was demonstrated in Gata1-deficient mice which suffer from early embryonic death (E10.5–11.5) and an inability to complete primitive and definitive erythroid differentiation [25,26]. Gata1 is expressed in HSCs and common myeloid and/or lymphoid progenitors. It is also crucial for the development of the megakaryocyte lineage [27] and for the survival of erythrocyte precursors [28,29]. Gata1 downregulates cofactors that are necessary for granulocyte–monocyte and lymphoid development, including Spi1 (PU.1), Il7 and Pax5 [30,31], while promoting megakaryocyte and erythrocyte commitment. Gata1 is also expressed in eosinophils and mast cells, where it plays a role in their terminal differentiation [16,17]. Functionally, Gata1 is involved in cell cycle regulation. In the context of erythroid maturation, it was shown to induce G1 arrest by targeting a number of key cell cycle regulators, which allows the cells to undergo maturation, driven by a Gata1-dependent erythroid gene expression programme [32].

2.2. Gata2

Gata2 is a master regulator of haematopoiesis. It is expressed in HSCs, multipotent haematopoietic progenitors, megakaryocytes, erythroid precursors, eosinophils and mast cells. Its deletion leads to embryonic death at E10.5 and a complete disruption of definitive haematopoiesis [33]. This is at the level of HSCs, as Gata2 is required for their emergence (as discussed further below) and their subsequent survival in a dose-dependent fashion [18,19,34]. However, while Gata2 is required for the proliferation and survival of multipotent haematopoietic progenitors and mast cell formation, it is dispensable for the terminal differentiation of erythroid cells and macrophages [35].

2.3. Gata3

Gata3 has been extensively studied in the context of innate and adaptive lymphoid development, where it regulates

differentiation and cell fate determination at various levels (for an extensive recent review see [8]). Specifically, it was found to be essential for the development, maintenance, survival and proliferation of early T-cell progenitors, as ES cells with a deleted *Gata3* gene were able to contribute to the B-cell, myelomonocytic and erythroid lineages but not thymocytic or T-cell lineages in chimera studies [36]. It was subsequently demonstrated that *Gata3* is required to induce and seal the T-cell fate in early lymphoid progenitors, while repressing the B lymphoid programme [37,38]. Within the T-cell lineage, *Gata3* is a master regulator of T helper type 2 cells (Th2). It regulates the differentiation of Th2 cells by controlling genes that encode Th2 cytokines *Il4*, *Il5* and *Il13* [39]. It appears, however, that *Gata3* levels need to be carefully controlled throughout thymocyte development as levels that are too high are cytotoxic, and levels that are too low cause developmental failure [40]. Indeed, enforced expression of *Gata3* in the T-cell lineage caused a maturation arrest in the cytotoxic T-cell lineage and promoted the formation of thymic lymphoblastoid tumours [41], and overexpression of *Gata3* at early fetal thymocyte stages redirected their differentiation towards the mast cell lineage [42].

Within the branch of innate immunity, *Gata3* is central to the development of the recently discovered innate lymphoid cells (ILCs), especially the ILC2 lineage [43,44], a subset of ILC3 cells [45] and a subset of ILC1-derived, tissue-resident NK cells [46,47]. Thus, *Gata3* is not necessary for the development of classic (NK) cells, but is crucial for a specialized subset of them. It is important for the terminal differentiation of NK cells and their exit from the bone marrow, and is crucial for the maintenance of liver-resident NK cells [48].

The importance of *GATA3* in lymphoid development and function is further highlighted by the fact that *GATA3* has also been implicated in T-cell acute lymphoblastic leukaemia (T-ALL). Together, T-cell acute lymphocytic leukaemia 1 (*TAL1*), *RUNX1* and *GATA3* form a positive interconnected auto-regulatory loop that directly activates the *MYB* oncogene, thus reinforcing and stabilizing the oncogenic programme that contributes to malignant transformation [49]. In addition, whole genome sequencing of patients with early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL), an aggressive subtype of T-ALL, has revealed *GATA3* inactivating lesions disrupting haematopoietic development [50]. *GATA3* has also been linked to other types of lymphoid malignancies. In a genomic profiling study, a *GATA3* single-nucleotide polymorphism genotype has been identified in a subtype of childhood acute lymphoblastic leukaemia (ALL), Philadelphia chromosome-positive ALL (Ph-like ALL), that has been associated with early treatment response, higher risk of relapse and overall poor prognosis [51]. And in anaplastic large cell lymphoma, the absence of the *GATA3* protein in addition to the presence of suppressive histone (H3K27) trimethylation at the *GATA3* promoter suggests epigenetic regulation of *GATA3* as a mechanism involved in disease pathogenesis [52].

Gata3 is also highly expressed in the long-term repopulating HSC (LT-HSC) population [53–55]. Using *Gata3*-null mice (deleted postnatally with *Mx1-Cre*), *Ku et al.* [56] have shown that *Gata3* deletion results in the production of lower numbers of adult LT-HSCs, and that a lower number of these *Gata3*-deficient LT-HSCs are in cycle. This suggests that *Gata3* is necessary for maintaining normal numbers of LT-HSCs, and that it regulates their entry into the cell cycle. However, by using a conditional *Gata3* knockout mouse line crossed to a

Table 1. Tissue-specific functions of *Gata3*.

system	function	reference
skin and hair	generation of skin selective barrier	[62–64]
	promotion of progenitor differentiation in the hair	
	follicle and proper hair structure	
kidney	nephric duct development	[65,66]
fat	inhibition of adipocyte differentiation	[67]
inner ear	cochlea morphology	[68]
mammary gland	mammary gland morphology	[69,70]
haematopoietic system	T-cell development	[36]
	Th2 commitment	[39]
	ILCs	[43–45]
	NK subsets	[46–48]
	Cell cycle regulation in adult HSCs	[56,58]
	non-cell autonomous role in embryonic HSC production	[20]
SNS	essential for the production of catecholamines	[71,72]
	promotes survival of sympathetic neurons in both adults and embryos	

Vav-Cre line, *Buza-Vidas et al.* [57] have shown that deletion of *Gata3* from HSCs after their emergence in the embryo does not affect the ability of HSCs to expand normally and that their numbers remain unaffected in the bone marrow after birth. Moreover, they reported that *Gata3* deletion does not affect the ability of HSCs to self-renew [57].

More recently, *Frelin et al.* [58] published data suggesting that *Gata3* controls the balance of LT-HSC self-renewal and differentiation by regulating their reprogramming from LT-HSC to intermediate term HSCs (IT-HSC). IT-HSCs are important for maintaining blood counts at steady state. They differ from LT-HSCs in that they are able to generate myeloid and erythroid progeny for 12 weeks [53,54,59], are more abundant than LT-HSCs (three times higher) [53,60], are more proliferative, and exit the quiescent state of the cell cycle more frequently than LT-HSCs: every 10–20 days compared to 50–100 days in LT-HSCs [61]. However, the precise function of *Gata3* in adult HSCs requires further investigation.

3. *Gata3* in development

Gata3 plays a major role in cell lineage specification and development in a variety of cells, tissues and organs during embryogenesis (table 1), including adipocytes [67], kidney [65], mammary gland [69], skin [62,73] and sympathetic nervous system (SNS) [63,71,74]. Not only does the study of

Gata3 activity in these different systems provide us with important clues about the molecular details of Gata3 function, it has also demonstrated that due to the close proximity of developing systems in the embryo, Gata3 action in one tissue can influence the development of a neighbouring tissue [20].

3.1. Skin and hair

Gata3 is essential for stem cell lineage determination in the skin. It is expressed at the onset of inner root sheath (IRS) cell specification in hair follicles. When *Gata3* was deleted using a LacZ knock-in, IRS progenitors failed to differentiate to form IRS, leading to the production of a defective hair structure [73]. In addition, Gata3 is the most highly expressed member of the GATA family in the interfollicular epidermis. The specific deletion of *Gata3* from the epidermal layer, using a *keratin-14-Cre* (*K14-Cre*) mouse line, proved to be prenatally lethal due to impairment of the skin selective barrier. Those mice showed defects in skin differentiation, abnormal hair follicle organization and delayed hair growth and maintenance. Genomic analysis of the mice revealed defective lipid biosynthesis. This could be attributed to the loss of lipid acetyltransferase gene (*Agpat5*), a gene that is a direct target of Gata3 [62,64]. Interestingly, Gata3 has previously been linked to adipogenesis where it was shown to inhibit adipocyte differentiation [67].

3.2. Kidney

Gata3 is the only GATA factor that is expressed in the urogenital system prior to E12.5. It is necessary for the normal development of the nephric duct. Using a *HoxB7-Cre* transgenic line, Grote *et al.* [65,66] specifically deleted Gata3 from the nephric duct, which resulted in severe abnormalities in the urogenital system and revealed that Gata3 is required to prevent ectopic metanephric kidney duct formation and premature cell differentiation. Additionally, it was reported that Gata3 haploinsufficiency resulted in renal dysplasia.

Gata3 has also been implicated in clear cell renal cell carcinoma (cc-RCC), the most common subtype of RCC. Cooper *et al.* [75] uncovered that when Gata3 expression was downregulated by promoter hypermethylation, it resulted in decreased expression of type III TGF- β receptor (*T β RIII*), which is a betaglycan protein with tumour suppressor features [75].

3.3. Inner ear

Gata3 is widely expressed in several cell types during ear development, including inner hair cells, outer hair cells as well as supportive cells [76–78]. As a consequence, the entire cochlea of the inner ear shows significant degeneration in mice heterozygous for *Gata3*, which leads to hearing loss [68]. This is mirrored in patients with HDR syndrome, who have only one functional copy of *GATA3* and who suffer from hypoparathyroidism, deafness and renal defects [79,80].

3.4. Mammary gland

Gata3 is crucial for mammary gland development. It is the transcription factor with the highest expression in the mammary epithelium as shown by genome-wide transcript analysis [70]. When *Gata3* was specifically deleted from the mammary epithelium at the onset of puberty, using the murine mammary

tumour virus (MMTV) promoter-Cre recombinase (MMTV-Cre), the mammary glands failed to develop terminal end buds (TEBs), resulting in abnormal ductal structures [69,70].

Its crucial role in the mammary gland is supported by the detection of GATA3 mutations in around 10% of human breast cancers. While the range of somatic mutations is varied, they cluster mainly in the highly conserved C-terminal second zinc finger [81]. Data from *in vitro* and *in vivo* studies suggest that GATA3 acts as a tumour suppressor gene. In a murine luminal breast cancer model, the loss of *Gata3* resulted in tumour progression and tumour dissemination [82]. More specifically, GATA3 expression was shown to inhibit breast cancer growth and pulmonary metastasis by repressing metastasis-associated genes such as *ID1*, *ID3*, *KRTHB1*, *LY6E* and *RARRES3* [83], and restoration of Gata3 expression in a breast cancer mouse model induced breast cancer differentiation and suppressed its dissemination [82]. Moreover, GATA3 was found to promote the expression of microRNA-29b (miR-29b), which in turn induces differentiation, suppresses metastasis and changes the tumour microenvironment [84]. In addition, low expression of GATA3 was associated with a poor survival rate and more aggressive disease, whereas GATA3-expressing breast cancer patients had a better prognosis, were less likely to relapse, and had a better overall survival rate [85]. The involvement of GATA3 in breast cancer, however, is complex as it was also shown to promote the growth of oestrogen-responsive tumours through direct binding to and activation of the oestrogen receptor α (*ER α*) gene [86]. ER α -positive tumours display a more differentiated phenotype and are generally less aggressive, which may be another reason why GATA3 expression in breast cancer is associated with a more favourable prognosis [87–89].

3.5. Sympathetic nervous system

Gata3 is essential for the development of the SNS [63,71,72,74,90]. In fact, this is the reason why *Gata3* deletion is embryonically lethal at around E11.5. This lethality was attributed to noradrenaline deficiency in the SNS and could be pharmacologically rescued by feeding the mothers DOPS, a synthetic catecholamine intermediate [63]. It was subsequently confirmed that Gata3 is essential for the production of catecholamines, the SNS mediators, through controlling the expression of tyrosine hydroxylase, the enzyme required for catecholamine synthesis. It also plays a major role in the survival of sympathetic neurons in both adults and embryos [71,72].

4. *Gata3* in haematopoietic stem cell emergence

The process of HSC emergence is highly conserved in vertebrates and is closely linked to vascular development (reviewed in [91,92]). It has been most intensely studied in the intra-embryonic aorta–gonad–mesonephros (AGM) region, where the first directly transplantable HSCs emerge at E10.5 in the mouse [93,94]. Haematopoietic stem and progenitor cell emergence involves activation of a haematopoietic transcriptional programme in a subset of endothelial cells, termed haemogenic endothelial cells, within the major arterial vessels of the embryo, such as the dorsal aorta within the AGM [95–97]. These haemogenic endothelial cells then undergo major structural and morphological changes that allow them




Figure 1. *Gata3* expression in the AGM region. Images show cryosections of *Gata3*^{+Lz} [114] E11.5 embryos stained with X-Gal for β -galactosidase activity (blue) and counterstained with Neutral Red. Ao, aorta; MD, mesonephric duct; Mes, mesenchyme; SNS, sympathetic nervous system; asterisks indicate *Gata3* staining underneath haematopoietic clusters; arrowheads point to individual *Gata3*-expressing endothelial cells.

to round up and detach from the endothelium as haematopoietic stem and progenitor cells. Localized production of de novo blood cells can be detected in tissue sections as clusters of cells co-expressing endothelial and haematopoietic markers that are attached to the endothelium, and has recently been captured by live imaging [98–100]. This endothelial-to-haematopoietic transition (EHT) is acutely dependent on the transcription factor Runx1 [101]. In its absence, haemogenic endothelial cells undergo apoptosis [100], no intra-aortic clusters are formed [102–104] and the generation of definitive haematopoietic stem and progenitor cells is disrupted [105,106].

The recent development of an elegant *ex vivo* co-aggregation explant culture system has revealed additional maturation stages that haemogenic endothelial cells have to undergo before they become fully functional HSCs [107–109]. There are at least three intermediate states as haemogenic endothelial cells mature first into pro-HSCs, then type I pre-HSCs and eventually via type II pre-HSCs into adult-type HSCs that can directly repopulate adult recipients. These stages can be distinguished temporally and through the sequential upregulation of the haematopoiesis-associated cell surface markers CD41, CD43 and CD45 [107].

A day after their emergence in the dorsal aorta and associated vitelline and umbilical arteries, HSCs are also detected in the yolk sac and the placenta [93,110–112]. Their presence in these tissues is only temporary as they eventually go on to colonize the fetal liver which becomes the major haematopoietic organ in the embryo from E12.5 until birth when HSCs relocate to the bone marrow.

Gata3 is expressed in the sites of intraembryonic haematopoietic cell generation in the mouse (AGM and its precursor, the para-aortic splanchnopleura) [20,113] (figure 1), zebrafish [115], chicken [116], human [117] and in *Xenopus* [118,119]. In the mouse embryo, *Gata3* is expressed at low level at E8.5 in the splanchnic mesoderm [113]. However, by E11.5 *Gata3* is expressed at high levels throughout the embryo. At this stage, *Gata3* deletion was embryonically lethal, death occurring concomitantly with the onset of definitive haematopoiesis in the fetal liver [21]. *Gata3* knockout embryos were shown to have growth retardation, along with severe deformities in spinal cord and brain, massive internal haemorrhage, anaemia and defective liver haematopoiesis, i.e. definitive haematopoiesis, suggesting that *Gata3* is essential for the development of various systems [21]. Yolk sac (YS) haematopoiesis was

normal, which corresponds with the fact the *Gata3* is not expressed in the YS [113]. Specifically, in an *in vitro* culture system, the colonies that resulted from the YS of *Gata3* knockout embryos, compared to their wild-type and heterozygous littermates, were normal, indicating the maintenance of primitive erythropoiesis. However, the colony numbers from the fetal liver of the knockout embryos were low compared to the wild-type and heterozygous littermates, indicating that *Gata3* disruption severely affects definitive haematopoiesis [21].

4.1. The sympathetic nervous system as part of the haematopoietic stem cell niche

The observation that definitive haematopoiesis is affected in *Gata3*^{-/-} embryos [21] and that *Gata3* is expressed in the AGM [113] (figure 1) suggested that *Gata3* may also be involved in HSC emergence. Furthermore, expression analyses and sorting of specific cell populations followed by transplantation into immunocompromised mice led to the proposal that defined structures located ventrally to the dorsal aorta, termed sub-aortic patches, contain HSCs and/or their precursors and that these expressed *Gata3* [113,120]. The cells in these patches were also found to co-express *Gata2*.

Gata3 was also identified as a potential AGM haematopoiesis regulator in expression profiling studies [121]. This study comprised three comparisons: (i) HSC containing region (middle part of the dorsal aorta) versus a region without HSCs (caudal and rostral part of the aorta); (ii) the microenvironment of HSCs before and after their emergence, i.e. the aorta with the immediate mesenchyme of E9–E10 versus E11; and (iii) using *Ly-6A GFP* transgenic embryos, which express GFP in all embryonic HSCs and their precursors, populations enriched for HSCs (E11 *Ly-6A GFP*⁺ cells) or their precursors (E9 *Ly-6A GFP*⁺ cells) were compared. *Gata3* was found to be upregulated in two of the three comparisons (ii and iii), i.e. in tissues surrounding the dorsal aorta specifically at the time of HSC emergence in the AGM and in HSC-enriched populations: E11 *Ly-6A GFP*⁺ cells.

A role for *Gata3* in HSC production in the AGM was subsequently confirmed [20]. Germline-deleted *Gata3*^{-/-} AGMs contained fewer *Ly-6A-GFP*⁺ aortic endothelial cells and showed reduced intra-aortic cluster formation. Most importantly, HSC activity in transplantation assays was severely




Figure 2. *Gata2* expression in *Gata3* wild-type (WT) and knockout (KO) AGMs. Images of *in situ* hybridization with a *Gata2* riboprobe on cryosections from E11.5 *Gata3*^{+/+} (left) and *Gata3*^{-/-} [21] (right) embryos. Ao, aorta; MD, mesonephric duct; SNS, sympathetic nervous system.

reduced in *Gata3*^{-/-} and *Gata3*^{+/-} AGMs. Interestingly, transplantation of *Gata3*-LacZ⁺ and *Gata3*-LacZ⁻ AGM cells clearly assigned repopulation activity to the *Gata3*-LacZ⁻ population, strongly suggesting that *Gata3* is not expressed in newly formed HSCs, but performs a non-cell autonomous role via the AGM haematopoietic microenvironment [20].

One of the components of the AGM haematopoietic microenvironment turned out to be the co-developing SNS. It had previously been reported that the SNS plays a major role in the mobilization [122,123] and proliferation [124] of adult HSCs. The fact that *Gata3* deletion affected both the SNS [63] as well as HSC production [20] in the AGM suggested the intriguing possibility that a functional interplay between the haematopoietic system and SNS already occurred at the time when these first develop during embryogenesis. Indeed, it was then demonstrated that external provision of catecholamines to *Gata3*-deficient embryos rescued the HSC defect, confirming that *Gata3* regulates HSC numbers through catecholamine production [20]. This indicates that HSC emergence in the AGM should be investigated as a part of a whole developmental process that is influenced by neighbouring tissues [20,121]. It also suggests that the previously described sub-aortic patches [113,120] may, in fact, have been cells of the SNS as they are known to co-express *Gata3* and *Gata2* [20,71] (figures 1 and 2). This does not rule out, however, that there may be individual *Gata2* and *Gata3* expressing mesenchymal HSC precursors [125].

4.2. A role for *Gata3* in haematopoietic stem cell precursors

In addition to its role in the AGM HSC microenvironment (via the SNS) described above, there is also evidence that *Gata3* may contribute to the specification of the definitive haematopoietic lineage. Manaia *et al.* [113] analysed the expression of *Gata3* and *Lmo2* in mouse embryonic development to understand the mechanisms involved in the generation of definitive HSCs. Interestingly, they found that *Gata3* and *Lmo2* are expressed concomitantly in the caudal embryonic mesoderm where haematopoietic cluster-bearing vessels develop, suggesting an involvement in cell fate determination. Another observation of their study was that *Gata3*

expression is restricted to sites involved in definitive haematopoiesis. *Gata3* is expressed in the environment from which intraembryonic precursors emerge, and in the developing haematopoietic sites before their colonization. *Gata3* was expressed both in the thymic rudiment until the first migrants arrived, and in the septum transversum before it gives rise to the fetal liver. However, no CD45⁺ haematopoietic cells were present within those sites at that developmental stage [113].

More recently, *Gata3* was also found to be upregulated in a subset of E10.5 endothelial cells that express GFP under the control of the *Runx1* + 23 enhancer element (23GFP⁺) that was described to mark haemogenic endothelial cells [97], indicating a possible involvement in HSC and progenitor generation. In addition, *Gata3* expression increased upon *Notch1* signalling induction, which expands the haemogenic endothelial population, and enhanced their haematopoietic potential [126]. Indeed, we found *Gata3* expression in individual endothelial cells, often in the vicinity of haematopoietic clusters (figure 1); however, further studies are required to determine if *Gata3* plays a functional role in haemogenic endothelium and the EHT.

4.3. *Gata3* expression in other compartments of the embryonic haematopoietic stem cell microenvironment

Gata3 expression is also found in individual cells in the sub-aortic mesenchyme of the AGM region (figure 1). Expression in this stromal compartment is restricted to the ventral side of the dorsal aorta, where HSCs are preferentially located [127]. In fact, *Gata3*-expressing cells were often detected just underneath intra-aortic haematopoietic cell clusters [20]. This mesenchymal expression disappears after E12.5, when intraembryonic clusters cease to be generated [113]. A number of known regulators of HSC emergence are expressed in cells of the sub-aortic ventral mesenchyme including *Bmp4*, *Scf*, *Runx1*, *Bmper*, *Thpo* and *Dlk1*, demonstrating that this cell compartment forms an important embryonic HSC niche [128–133]. Furthermore, cells with mesenchymal stem/stromal cell potential have been detected specifically in the AGM at the time of HSC emergence

[134]. The sub-aortic mesenchymal cell compartment, however, is a very heterogeneous population, and it is currently unknown which cells participate in the niche for emerging HSCs and whether this compartment contains and may even be maintained by mesenchymal stem cells. It is also currently not clear whether *Gata3* plays an important role in the mesenchymal stroma of the AGM.

Gata3 is expressed in one further cell compartment in the AGM region, the mesonephric ducts within the urogenital ridges (UGRs) [20] (figure 1). It was recently demonstrated that UGRs do not contain HSCs or their precursors, but their presence promotes HSC formation in the neighbouring aorta in co-aggregation studies, indicating that UGRs also form part of the HSC supportive microenvironment [133]. Yet, while it has been established that *Gata3* expression in the UGRs is required for kidney development [65], it is currently unknown whether it promotes the production of HSC-supportive factors in these structures. However, the fact that *Gata3* is expressed in several different cell types in the AGM relevant to haematopoiesis highlights its complex involvement in the production of the first HSCs.

5. Concluding remarks

Gata3 is essential for the development of several types of cells, organs and tissues (table 1), and its disruption during development results in severe defects and impairment in those systems, leading to embryonic death at midgestation following germline deletion [21]. Analysis of the phenotypes of *Gata3* deletion in these different systems has revealed that *Gata3* is often expressed in the stem and progenitor compartment where it regulates cell fate determination and differentiation. In the developing kidney [65,66] and preadipocytes [67], it seems to prevent premature differentiation, whereas in skin [73] and mammary gland [69] it promotes progenitor differentiation. Overall, however, its function is to ensure correct tissue morphogenesis. Considering this crucial function, it is therefore not surprising that *Gata3* has been implicated in a number of different cancer types.

How *Gata3* functions at the molecular level is not well understood in many of these systems. One common underlying theme may be regulation of the cell cycle as has been suggested for the role of *Gata3* in adult HSCs [56,58]. *Gata3* may allow tissue-specific progenitors to differentiate by blocking their cell cycle, and this may also be how haemogenic endothelial cells can then undergo the morphological changes as they become blood cells. However, it is also clear that *Gata3* activates tissue-specific genes such as tyrosine hydroxylase in the SNS and lipid acetyltransferase in the skin. Some of the genes that *Gata3* activates during metastasis may also be relevant for the EHT.

GATA factors have often been observed in common complexes and have been seen to cross-regulate each other, with the GATA switch being such an example. Within the AGM, *Gata2* and *Gata3* expression overlaps in several cell compartments (figures 1 and 2) and they are both involved in HSC production in the AGM, but the nature of their interaction appears to be tissue-specific. Both are expressed in the urogenital ridges, but while *Gata3* is expressed specifically in the mesonephric ducts, *Gata2* expression is found in the tissue directly surrounding the ducts. Interestingly, however, the expression of *Gata2* around the ducts disappears in *Gata3*^{-/-}




Figure 3. *Gata3* involvement in AGM haematopoiesis. Schematic diagram of a transverse section through an E11.5 AGM region, highlighting the cell compartments that express *Gata3*. *Gata3*-positive cells (green) are found within the endothelial layer (yellow) of the dorsal aorta (Ao), in the mesonephric duct (MD), within the subaortic mesenchyme (orange; Mes) and in the sympathetic nervous system (SNS). Blood cells are shown in red. The light green cell depicts the putative involvement of *Gata3* in the endothelial-to-haematopoietic transition. Curly arrows illustrate contributions made by the different components of the microenvironment to EHT/HSC support, of which only catecholamines are currently known to be *Gata3*-dependent. UGR, urogenital ridges.

embryos [20] (figure 2). Both have been detected in the haemogenic endothelium, but the deletion of *Gata2* affects the development of definitive haematopoietic stem and progenitor cells much more severely, suggesting that it may act upstream of *Gata3* here or performs a much more crucial function in the EHT. In the SNS, on the other hand, *Gata3* is clearly upstream of *Gata2*, as *Gata2* expression in sympathoadrenal cells disappears in *Gata3*-null embryos, while its expression in the aortic endothelium remains [20] (figure 2).

Very little is currently known about the upstream regulators of *Gata3* in the different AGM cell compartments. *Phox2b* is required for *Gata3* expression in the SNS [71]. Considering the crucial roles of *Gata2* and *Runx1* in the EHT, these two transcription factors may well be upstream of *Gata3* in haemogenic endothelial cells. In addition, *Notch1* was shown to induce *Gata3* in an embryonic stem cell model of the EHT [126]. As *Notch1* is also crucial for HSC emergence in the AGM [135], it is likely that *Gata3* dependence on *Notch* signalling is conserved *in vivo*.

Current data have shown that *Gata3* plays several roles in the embryonic and adult haematopoietic system. However, the similarities and differences in these roles require further dissection. For example, in development, *Gata3* was shown to regulate HSCs by means of controlling SNS development and the secretion of HSC-supportive catecholamines [20]; however, its expression patterns in the HSC microenvironment suggest a more complex role in haematopoietic stem and progenitor cell regulation (figure 3). In the sub-aortic mesenchymal compartment, *Gata3* expression is restricted to a few scattered cells on the ventral side. The fact that it

has been associated with the stem and progenitor compartment in several tissues makes it tempting to speculate that its expression marks mesenchymal stem cells. Dissecting its function in each cell type and identifying its role in HSC precursors and the HSC regulatory microenvironment is an intricate process and will require tissue-specific deletion.

In addition, the scarcity of these cells and the dynamic nature of the developing embryo add more challenges to identifying the role of Gata3 in the emerging definitive haematopoietic system. However, the availability of powerful tools such as RNA-Seq, which can now be performed on a single-cell level, will help to identify the genetic programme of these individual cell types and contribute to a better

understanding of the nature and function of these cells and how Gata3 may influence their function. It is, however, very likely that the haematopoietic phenotype described in germline-deleted *Gata3*-null embryos [20,21] is a compound phenotype resulting from the effects of Gata3 deletion in the various AGM cell types.

Data accessibility. This article has no additional data.

Competing interests. We declare we have no competing interests.

Funding. Our Gata3-related work was supported by an Intermediate Fellowship from the Kay Kendall Leukaemia Fund (K.O.) and by a fellowship from the King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard (N.Z.).

References

- Dzierzak E, Bigas A. 2018 Blood development: hematopoietic stem cell dependence and independence. *Cell Stem Cell* **22**, 639–651. (doi:10.1016/j.stem.2018.04.015)
- Lentjes MH, Niessen HE, Akiyama Y, de Bruine AP, Melotte V, van Engeland M. 2016 The emerging role of GATA transcription factors in development and disease. *Expert Rev. Mol. Med.* **18**, e3. (doi:10.1017/erm.2016.2)
- Fujiwara T, O'Geen H, Keles S, Blahnik K, Linnemann AK, Kang YA, Choi K, Farnham PJ, Bresnick EH. 2009 Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. *Mol. Cell* **36**, 667–681. (doi:10.1016/j.molcel.2009.11.001)
- Katsumura KR, Bresnick EH, Group GFM. 2017 The GATA factor revolution in hematology. *Blood* **129**, 2092–2102. (doi:10.1182/blood-2016-09-687871)
- Martin DI, Orkin SH. 1990 Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-E1/Eryf 1. *Genes Dev.* **4**, 1886–1898. (doi:10.1101/gad.4.11.1886)
- Newton A, Mackay J, Crossley M. 2001 The N-terminal zinc finger of the erythroid transcription factor GATA-1 binds GATC motifs in DNA. *J. Biol. Chem.* **276**, 35 794–35 801. (doi:10.1074/jbc.M106256200)
- Trainor CD, Omichinski JG, Vandergon TL, Gronenborn AM, Clore GM, Felsenfeld G. 1996 A palindromic regulatory site within vertebrate GATA-1 promoters requires both zinc fingers of the GATA-1 DNA-binding domain for high-affinity interaction. *Mol. Cell Biol.* **16**, 2238–2247. (doi:10.1128/MCB.16.5.2238)
- Tindemans I, Serafini N, Di Santo JP, Hendriks RW. 2014 GATA-3 function in innate and adaptive immunity. *Immunity* **41**, 191–206. (doi:10.1016/j.immuni.2014.06.006)
- Bates DL, Chen Y, Kim G, Guo L, Chen L. 2008 Crystal structures of multiple GATA zinc fingers bound to DNA reveal new insights into DNA recognition and self-association by GATA. *J. Mol. Biol.* **381**, 1292–1306. (doi:10.1016/j.jmb.2008.06.072)
- Hosoya-Ohmura S, Lin YH, Herrmann M, Kuroha T, Rao A, Moriguchi T, Lim KC, Hosoya T, Engel JD. 2011 An NK and T cell enhancer lies 280 kilobase pairs 3' to the *gata3* structural gene. *Mol. Cell Biol.* **31**, 1894–1904. (doi:10.1128/MCB.05065-11)
- Lakshmanan G, Lieuw KH, Lim KC, Gu Y, Grosveld F, Engel JD, Karis A. 1999 Localization of distant urogenital system-, central nervous system-, and endocardium-specific transcriptional regulatory elements in the GATA-3 locus. *Mol. Cell Biol.* **19**, 1558–1568. (doi:10.1128/MCB.19.2.1558)
- Burch JB. 2005 Regulation of GATA gene expression during vertebrate development. *Semin. Cell Dev. Biol.* **16**, 71–81. (doi:10.1016/j.semcdb.2004.10.002)
- Ranganath S, Murphy KM. 2001 Structure and specificity of GATA proteins in Th2 development. *Mol. Cell Biol.* **21**, 2716–2725. (doi:10.1128/MCB.21.8.2716-2725.2001)
- Takahashi S *et al.* 2000 GATA factor transgenes under GATA-1 locus control rescue germline GATA-1 mutant deficiencies. *Blood* **96**, 910–916.
- Tsai FY, Browne CP, Orkin SH. 1998 Knock-in mutation of transcription factor GATA-3 into the GATA-1 locus: partial rescue of GATA-1 loss of function in erythroid cells. *Dev. Biol.* **196**, 218–227. (doi:10.1006/dbio.1997.8842)
- Harigae H *et al.* 1998 Differential roles of GATA-1 and GATA-2 in growth and differentiation of mast cells. *Genes Cells* **3**, 39–50. (doi:10.1046/j.1365-2443.1998.00166.x)
- Iwasaki H, Mizuno S, Wells RA, Cantor AB, Watanabe S, Akashi K. 2003 GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. *Immunity* **19**, 451–462. (doi:10.1016/S1074-7613(03)00242-5)
- de Pater E *et al.* 2013 Gata2 is required for HSC generation and survival. *J. Exp. Med.* **210**, 2843–2850. (doi:10.1084/jem.20130751)
- Gao X, Johnson KD, Chang YI, Boyer ME, Dewey CN, Zhang J, Bresnick EH. 2013 Gata2 cis-element is required for hematopoietic stem cell generation in the mammalian embryo. *J. Exp. Med.* **210**, 2833–2842. (doi:10.1084/jem.20130733)
- Fitch SR, Kimber GM, Wilson NK, Parker A, Mirshekar-Syahkal B, Gottgens B, Medvinsky A, Dzierzak E, Ottersbach K. 2012 Signaling from the sympathetic nervous system regulates hematopoietic stem cell emergence during embryogenesis. *Cell Stem Cell* **11**, 554–566. (doi:10.1016/j.stem.2012.07.002)
- Pandolfi PP, Roth ME, Karis A, Leonard MW, Dzierzak E, Grosveld FG, Engel JD, Lindenbaum MH. 1995 Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. *Nat. Genet.* **11**, 40–44. (doi:10.1038/ng0995-40)
- Bresnick EH, Lee HY, Fujiwara T, Johnson KD, Keles S. 2010 GATA switches as developmental drivers. *J. Biol. Chem.* **285**, 31 087–31 093. (doi:10.1074/jbc.R110.159079)
- Grass JA, Boyer ME, Pal S, Wu J, Weiss MJ, Bresnick EH. 2003 GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. *Proc. Natl Acad. Sci. USA* **100**, 8811–8816. (doi:10.1073/pnas.1432147100)
- Suzuki M *et al.* 2013 GATA factor switching from GATA2 to GATA1 contributes to erythroid differentiation. *Genes Cells* **18**, 921–933. (doi:10.1111/gtc.12086)
- Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH. 1996 Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. *Proc. Natl Acad. Sci. USA* **93**, 12 355–12 358. (doi:10.1073/pnas.93.22.12355)
- Pevny L, Simon MC, Robertson E, Klein WH, Tsai SF, D'Agati V, Orkin SH, Costantini F. 1991 Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. *Nature* **349**, 257–260. (doi:10.1038/349257a0)
- Chang AN, Cantor AB, Fujiwara Y, Lodish MB, Droho S, Crispino JD, Orkin SH. 2002 GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. *Proc. Natl Acad. Sci. USA* **99**, 9237–9242. (doi:10.1073/pnas.142302099)
- Chiba T, Nagata Y, Kishi A, Sakamaki K, Miyajima A, Yamamoto M, Engel JD, Todokoro K. 1993 Induction of erythroid-specific gene expression in lymphoid cells. *Proc. Natl Acad. Sci. USA* **90**, 11 593–11 597. (doi:10.1073/pnas.90.24.11593)

29. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ. 1999 GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. *Blood* **94**, 87–96.
30. Heavey B, Charalambous C, Cobaleda C, Busslinger M. 2003 Myeloid lineage switch of *Pax5* mutant but not wild-type B cell progenitors by *C/EBP α* and GATA factors. *EMBO J.* **22**, 3887–3897. (doi:10.1093/emboj/cdg380)
31. Nerlov C, Querfurth E, Kulesa H, Graf T. 2000 GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. *Blood* **95**, 2543–2551.
32. Rylski M, Welch JJ, Chen YY, Letting DL, Diehl JA, Chodosh LA, Blobel GA, Weiss MJ. 2003 GATA-1-mediated proliferation arrest during erythroid maturation. *Mol. Cell Biol.* **23**, 5031–5042. (doi:10.1128/MCB.23.14.5031-5042.2003)
33. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, Alt FW, Orkin SH. 1994 An early haematopoietic defect in mice lacking the transcription factor GATA-2. *Nature* **371**, 221–226. (doi:10.1038/371221a0)
34. Ling KW, Ottersbach K, van Hamburg JP, Oziemlak A, Tsai FY, Orkin SH, Ploemacher R, Hendriks RW, Dzierzak E. 2004 GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells. *J. Exp. Med.* **200**, 871–882. (doi:10.1084/jem.20031556)
35. Tsai FY, Orkin SH. 1997 Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. *Blood* **89**, 3636–3643.
36. Ting CN, Olson MC, Barton KP, Leiden JM. 1996 Transcription factor GATA-3 is required for development of the T-cell lineage. *Nature* **384**, 474–478. (doi:10.1038/384474a0)
37. Garcia-Ojeda ME, Klein Wolterink RG, Lemaître F, Richard-Le Goff O, Hasan M, Hendriks RW, Cumano A, Di Santo JP. 2013 GATA-3 promotes T-cell specification by repressing B-cell potential in pro-T cells in mice. *Blood* **121**, 1749–1759. (doi:10.1182/blood-2012-06-440065)
38. Rothenberg EV. 2013 GATA-3 locks the door to the B-cell option. *Blood* **121**, 1673–1674. (doi:10.1182/blood-2013-01-477737)
39. Lee GR, Fields PE, Flavell RA. 2001 Regulation of IL-4 gene expression by distal regulatory elements and GATA-3 at the chromatin level. *Immunity* **14**, 447–459. (doi:10.1016/S1074-7613(01)00125-X)
40. Ho IC, Tai TS, Pai SY. 2009 GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. *Nat. Rev. Immunol.* **9**, 125–135. (doi:10.1038/nri2476)
41. Nawijn MC, Ferreira R, Dingjan GM, Kahre O, Drabek D, Karis A, Grosveld F, Hendriks RW. 2001 Enforced expression of GATA-3 during T cell development inhibits maturation of CD8 single-positive cells and induces thymic lymphoma in transgenic mice. *J. Immunol.* **167**, 715–723. (doi:10.4049/jimmunol.167.2.715)
42. Taghon T, Yui MA, Rothenberg EV. 2007 Mast cell lineage diversion of T lineage precursors by the essential T cell transcription factor GATA-3. *Nat. Immunol.* **8**, 845–855. (doi:10.1038/ni1486)
43. Hoyler T, Klose CS, Souabni A, Turqueti-Neves A, Pfeifer D, Rawlins EL, Voehringer D, Busslinger M, Diefenbach A. 2012 The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. *Immunity* **37**, 634–648. (doi:10.1016/j.immuni.2012.06.020)
44. Klein WRG, Serafini N, van Nimwegen M, Vosshenrich CA, de Bruijn MJ, Fonseca Pereira D, Veiga Fernandes H, Hendriks RW, Di Santo JP. 2013 Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5⁺ and IL-13⁺ type 2 innate lymphoid cells. *Proc. Natl Acad. Sci. USA* **110**, 10 240–10 245. (doi:10.1073/pnas.1217158110)
45. Serafini N, Klein Wolterink RG, Satoh-Takayama N, Xu W, Vosshenrich CA, Hendriks RW, Di Santo JP. 2014 *Gata3* drives development of ROR γ ⁺ group 3 innate lymphoid cells. *J. Exp. Med.* **211**, 199–208. (doi:10.1084/jem.20131038)
46. Samson SI *et al.* 2003 GATA-3 promotes maturation, IFN- γ production, and liver-specific homing of NK cells. *Immunity* **19**, 701–711. (doi:10.1016/S1074-7613(03)00294-2)
47. Vosshenrich CA *et al.* 2006 A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. *Nat. Immunol.* **7**, 1217–1224. (doi:10.1038/ni1395)
48. Ali AK, Oh JS, Vivier E, Busslinger M, Lee SH. 2016 NK cell-specific *gata3* ablation identifies the maturation program required for bone marrow exit and control of proliferation. *J. Immunol.* **196**, 1753–1767. (doi:10.4049/jimmunol.1501593)
49. Sanda T *et al.* 2012 Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. *Cancer Cell* **22**, 209–221. (doi:10.1016/j.ccr.2012.06.007)
50. Zhang J *et al.* 2012 The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* **481**, 157–163. (doi:10.1038/nature10725)
51. Perez-Andreu V *et al.* 2013 Inherited GATA3 variants are associated with pH-like childhood acute lymphoblastic leukemia and risk of relapse. *Nat. Genet.* **45**, 1494–1498. (doi:10.1038/ng.2803)
52. Joosten M, Seitz V, Zimmermann K, Sommerfeld A, Berg E, Lenze D, Leser U, Stein H, Hummel M. 2013 Histone acetylation and DNA demethylation of T cells result in an anaplastic large cell lymphoma-like phenotype. *Haematologica* **98**, 247–254. (doi:10.3324/haematol.2011.054619)
53. Benveniste P, Frelin C, Janmohamed S, Barbara M, Herrington R, Hyam D, Iscove NN. 2010 Intermediate-term hematopoietic stem cells with extended but time-limited reconstitution potential. *Cell Stem Cell* **6**, 48–58. (doi:10.1016/j.stem.2009.11.014)
54. Kent DG *et al.* 2009 Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. *Blood* **113**, 6342–6350. (doi:10.1182/blood-2008-12-192054)
55. Zhong JF *et al.* 2005 Gene expression profile of murine long-term reconstituting vs. short-term reconstituting hematopoietic stem cells. *Proc. Natl Acad. Sci. USA* **102**, 2448–2453. (doi:10.1073/pnas.0409459102)
56. Ku CJ, Hosoya T, Maillard I, Engel JD. 2012 GATA-3 regulates hematopoietic stem cell maintenance and cell-cycle entry. *Blood* **119**, 2242–2251. (doi:10.1182/blood-2011-07-366070)
57. Buza-Vidas N, Duarte S, Luc S, Bouriez-Jones T, Will PS, Jacobsen SE. 2011 GATA3 is redundant for maintenance and self-renewal of hematopoietic stem cells. *Blood* **118**, 1291–1293. (doi:10.1182/blood-2011-02-338046)
58. Frelin C *et al.* 2013 GATA-3 regulates the self-renewal of long-term hematopoietic stem cells. *Nat. Immunol.* **14**, 1037–1044. (doi:10.1038/ni.2692)
59. Dykstra B, Kent D, Bowie M, McCaffrey L, Hamilton M, Lyons K, Lee SJ, Brinkman R, Eaves C. 2007 Long-term propagation of distinct hematopoietic differentiation programs *in vivo*. *Cell Stem Cell* **1**, 218–229. (doi:10.1016/j.stem.2007.05.015)
60. Foudi A, Hochedlinger K, Van Buren D, Schindler JW, Jaenisch R, Carey V, Hock H. 2009 Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. *Nat. Biotechnol.* **27**, 84–90. (doi:10.1038/nbt.1517)
61. Wilson A *et al.* 2008 Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell* **135**, 1118–1129. (doi:10.1016/j.cell.2008.10.048)
62. Kurek D, Garinis GA, van Doorninck JH, van der Wees J, Grosveld FG. 2007 Transcriptome and phenotypic analysis reveals Gata3-dependent signalling pathways in murine hair follicles. *Development* **134**, 261–272. (doi:10.1242/dev.02721)
63. Lim KC, Lakshmanan G, Crawford SE, Gu Y, Grosveld F, Engel JD. 2000 *Gata3* loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. *Nat. Genet.* **25**, 209–212. (doi:10.1038/76080)
64. de Guzman Strong C *et al.* 2006 Lipid defect underlies selective skin barrier impairment of an epidermal-specific deletion of *Gata-3*. *J. Cell Biol.* **175**, 661–670. (doi:10.1083/jcb.200605057)
65. Grote D, Souabni A, Busslinger M, Bouchard M. 2006 Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. *Development* **133**, 53–61. (doi:10.1242/dev.02184)
66. Grote D, Boualía SK, Souabni A, Merkel C, Chi X, Costantini F, Carroll T, Bouchard M. 2008 *Gata3* acts downstream of β -catenin signaling to prevent ectopic metanephric kidney induction. *PLoS Genet.* **4**, e1000316. (doi:10.1371/journal.pgen.1000316)
67. Tong Q, Dalgin G, Xu H, Ting CN, Leiden JM, Hotamisligil GS. 2000 Function of GATA transcription factors in preadipocyte-adipocyte transition. *Science* **290**, 134–138. (doi:10.1126/science.290.5489.134)

68. van der Wees J *et al.* 2004 Hearing loss following Gata3 haploinsufficiency is caused by cochlear disorder. *Neurobiol Dis.* **16**, 169–178. (doi:10.1016/j.nbd.2004.02.004)
69. Asselin-Labat ML *et al.* 2007 Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. *Nat. Cell Biol.* **9**, 201–209. (doi:10.1038/ncb1530)
70. Kouros-Mehr H, Werb Z. 2006 Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. *Dev. Dyn.* **235**, 3404–3412. (doi:10.1002/dvdy.20978)
71. Tzarovina K, Pattyn A, Stubbusch J, Muller F, van der Wees J, Schneider C, Brunet JF, Rohrer H. 2004 Essential role of Gata transcription factors in sympathetic neuron development. *Development* **131**, 4775–4786. (doi:10.1242/dev.01370)
72. Tzarovina K, Reiff T, Stubbusch J, Kurek D, Grosveld FG, Parlato R, Schutz G, Rohrer H. 2010 The Gata3 transcription factor is required for the survival of embryonic and adult sympathetic neurons. *J. Neurosci.* **30**, 10 833–10 843. (doi:10.1523/JNEUROSCI.0175-10.2010)
73. Kaufman CK, Zhou P, Pasolli HA, Rendl M, Bolotin D, Lim KC, Dai X, Alegre ML, Fuchs E. 2003 GATA-3: an unexpected regulator of cell lineage determination in skin. *Genes Dev.* **17**, 2108–2122. (doi:10.1101/gad.1115203)
74. Moriguchi T *et al.* 2006 Gata3 participates in a complex transcriptional feedback network to regulate sympathoadrenal differentiation. *Development* **133**, 3871–3881. (doi:10.1242/dev.02553)
75. Cooper SJ *et al.* 2010 Loss of type III transforming growth factor- β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. *Oncogene* **29**, 2905–2915. (doi:10.1038/onc.2010.64)
76. Karis A, Pata I, van Doorninck JH, Grosveld F, de Zeeuw CI, de Caprona D, Fritzsche B. 2001 Transcription factor GATA-3 alters pathway selection of olivocochlear neurons and affects morphogenesis of the ear. *J. Comp. Neurol.* **429**, 615–630. (doi:10.1002/1096-9861(20010122)429:4<615::AID-CNE8>3.0.CO;2-F)
77. Lawoko-Kerali G, Rivolta MN, Holley M. 2002 Expression of the transcription factors GATA3 and Pax2 during development of the mammalian inner ear. *J. Comp. Neurol.* **442**, 378–391. (doi:10.1002/cne.10088)
78. Rivolta MN, Holley MC. 1998 GATA3 is downregulated during hair cell differentiation in the mouse cochlea. *J. Neurocytol.* **27**, 637–647. (doi:10.1023/A:1006951813063)
79. Muroya K *et al.* 2001 GATA3 abnormalities and the phenotypic spectrum of HDR syndrome. *J. Med. Genet.* **38**, 374–380. (doi:10.1136/jmg.38.6.374)
80. Van Esch H *et al.* 2000 GATA3 haplo-insufficiency causes human HDR syndrome. *Nature* **406**, 419–422. (doi:10.1038/35019088)
81. Cancer Genome Atlas Network. 2012 Comprehensive molecular portraits of human breast tumours. *Nature* **490**, 61–70. (doi:10.1038/nature11412)
82. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. 2008 GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. *Cancer Cell* **13**, 141–152. (doi:10.1016/j.ccr.2008.01.011)
83. Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguere V, Siegel PM, Bouchard M. 2009 GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. *Oncogene* **28**, 2634–2642. (doi:10.1038/onc.2009.126)
84. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. 2013 GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. *Nat. Cell Biol.* **15**, 201–213. (doi:10.1038/ncb2672)
85. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. 2006 Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. *J. Clin. Oncol.* **24**, 1656–1664. (doi:10.1200/JCO.2005.03.2755)
86. Eeckhoutte J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. 2007 Positive cross-regulatory loop ties GATA-3 to estrogen receptor α expression in breast cancer. *Cancer Res.* **67**, 6477–6483. (doi:10.1158/0008-5472.CAN-07-0746)
87. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. 2005 Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. *Cancer Res.* **65**, 11 259–11 264. (doi:10.1158/0008-5472.CAN-05-2495)
88. Parikh P, Palazzo JP, Rose LJ, Daskalakis C, Weigel RJ. 2005 GATA-3 expression as a predictor of hormone response in breast cancer. *J. Am. Coll. Surg.* **200**, 705–710. (doi:10.1016/j.jamcollsurg.2004.12.025)
89. Sorlie T *et al.* 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl Acad. Sci. USA* **98**, 10 869–10 874. (doi:10.1073/pnas.191367098)
90. Hong SJ, Choi HJ, Hong S, Huh Y, Chae H, Kim KS. 2008 Transcription factor GATA-3 regulates the transcriptional activity of dopamine β -hydroxylase by interacting with Sp1 and AP4. *Neurochem. Res.* **33**, 1821–1831. (doi:10.1007/s11064-008-9639-3)
91. Ciau-Uitz A, Monteiro R, Kirmizitas A, Patient R. 2014 Developmental hematopoiesis: ontogeny, genetic programming and conservation. *Exp. Hematol.* **42**, 669–683. (doi:10.1016/j.exphem.2014.06.001)
92. Medvinsky A, Rytsov S, Taoudi S. 2011 Embryonic origin of the adult hematopoietic system: advances and questions. *Development* **138**, 1017–1031. (doi:10.1242/dev.040998)
93. Medvinsky A, Dzierzak E. 1996 Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell* **86**, 897–906. (doi:10.1016/S0092-8674(00)80165-8)
94. Muller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E. 1994 Development of hematopoietic stem cell activity in the mouse embryo. *Immunity* **1**, 291–301. (doi:10.1016/1074-7613(94)90081-7)
95. Li Y *et al.* 2014 Inflammatory signaling regulates embryonic hematopoietic stem and progenitor cell production. *Genes Dev.* **28**, 2597–2612. (doi:10.1101/gad.253302.114)
96. Solaimani KP *et al.* 2015 Whole-transcriptome analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 in HSC generation. *J. Exp. Med.* **212**, 93–106. (doi:10.1084/jem.20140767)
97. Swiers G *et al.* 2013 Early dynamic fate changes in haemogenic endothelium characterized at the single-cell level. *Nat. Commun.* **4**, 2924. (doi:10.1038/ncomms3924)
98. Bertrand JY, Chi NC, Santoso B, Teng S, Stainer DY, Traver D. 2010 Haematopoietic stem cells derive directly from aortic endothelium during development. *Nature* **464**, 108–111. (doi:10.1038/nature08738)
99. Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C. 2010 *In vivo* imaging of haematopoietic cells emerging from the mouse aortic endothelium. *Nature* **464**, 116–120. (doi:10.1038/nature08764)
100. Kissa K, Herbomel P. 2010 Blood stem cells emerge from aortic endothelium by a novel type of cell transition. *Nature* **464**, 112–115. (doi:10.1038/nature08761)
101. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. 2009 Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. *Nature* **457**, 887–891. (doi:10.1038/nature07619)
102. Cai Z, de Bruijn M, Ma X, Dortland B, Luteijn T, Downing RJ, Dzierzak E. 2000 Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. *Immunity* **13**, 423–431. (doi:10.1016/S1074-7613(00)0042-X)
103. North T, Gu TL, Stacy T, Wang Q, Howard L, Binder M, Marin-Padilla M, Speck NA. 1999 Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. *Development* **126**, 2563–2575.
104. Yokomizo T, Dzierzak E. 2010 Three-dimensional cartography of hematopoietic clusters in the vasculature of whole mouse embryos. *Development* **137**, 3651–3661. (doi:10.1242/dev.051094)
105. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996 AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell* **84**, 321–330. (doi:10.1016/S0092-8674(00)80986-1)
106. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996 Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. *Proc. Natl Acad. Sci. USA* **93**, 3444–3449. (doi:10.1073/pnas.93.8.3444)
107. Rytsov S, Batsivari A, Bilotkach K, Paruzina D, Senserrich J, Nerushev O, Medvinsky A. 2014 Tracing the origin of the HSC hierarchy reveals an SCF-dependent, IL-3-independent CD43[−] embryonic precursor. *Stem Cell Reports* **3**, 489–501. (doi:10.1016/j.stemcr.2014.07.009)

108. Rybtsov S *et al.* 2011 Hierarchical organization and early hematopoietic specification of the developing HSC lineage in the AGM region. *J. Exp. Med.* **208**, 1305–1315. (doi:10.1084/jem.20102419)
109. Taoudi S, Gonneau C, Moore K, Sheridan JM, Blackburn CC, Taylor E, Medvinsky A. 2008 Extensive hematopoietic stem cell generation in the AGM region via maturation of VE-Cadherin⁺CD45⁺ pre-definitive HSCs. *Cell Stem Cell* **3**, 99–108. (doi:10.1016/j.stem.2008.06.004)
110. de Bruijn MF, Speck NA, Peeters MC, Dzierzak E. 2000 Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. *EMBO J.* **19**, 2465–2474. (doi:10.1093/emboj/19.11.2465)
111. Gekas C, Dieterlen-Lievre F, Orkin SH, Mikkola HK. 2005 The placenta is a niche for hematopoietic stem cells. *Dev. Cell* **8**, 365–375. (doi:10.1016/j.devcel.2004.12.016)
112. Ottersbach K, Dzierzak E. 2005 The murine placenta contains hematopoietic stem cells within the vascular labyrinth region. *Dev. Cell* **8**, 377–387. (doi:10.1016/j.devcel.2005.02.001)
113. Manaia A, Lemarchandel V, Klaine M, Max-Audit I, Romeo P, Dieterlen-Lievre F, Godin I. 2000 Lmo2 and GATA-3 associated expression in intraembryonic hemogenic sites. *Development* **127**, 643–653.
114. van Doorninck JH, van Der Wees J, Karis A, Goedknecht E, Engel JD, Coesmans M, Rutteman M, Grosveld F, De Zeeuw CI. 1999 GATA-3 is involved in the development of serotonergic neurons in the caudal raphe nuclei. *J. Neurosci.* **19**, RC12. (doi:10.1523/JNEUROSCI.19-12-j0002.1999)
115. Neave B, Rodaway A, Wilson SW, Patient R, Holder N. 1995 Expression of zebrafish GATA 3 (gta3) during gastrulation and neurulation suggests a role in the specification of cell fate. *Mech. Dev.* **51**, 169–182. (doi:10.1016/0925-4773(95)00351-7)
116. Leonard MW, Lim KC, Engel JD. 1993 Expression of the chicken GATA factor family during early erythroid development and differentiation. *Development* **119**, 519–531.
117. Labastie MC, Cortes F, Romeo PH, Dulac C, Peault B. 1998 Molecular identity of hematopoietic precursor cells emerging in the human embryo. *Blood* **92**, 3624–3635.
118. Bertwistle D, Walmsley ME, Read EM, Pizzey JA, Patient RK. 1996 GATA factors and the origins of adult and embryonic blood in *Xenopus*: responses to retinoic acid. *Mech. Dev.* **57**, 199–214. (doi:10.1016/0925-4773(96)00547-3)
119. Turpen JB, Kelley CM, Mead PE, Zon LI. 1997 Bipotential primitive-definitive hematopoietic progenitors in the vertebrate embryo. *Immunity* **7**, 325–334. (doi:10.1016/S1074-7613(00)80354-4)
120. Bertrand JY, Giroux S, Golub R, Klaine M, Jalil A, Boucontet L, Godin I, Cumano A. 2005 Characterization of purified intraembryonic hematopoietic stem cells as a tool to define their site of origin. *Proc. Natl Acad. Sci. USA* **102**, 134–139. (doi:10.1073/pnas.0402270102)
121. Mascarenhas MI, Parker A, Dzierzak E, Ottersbach K. 2009 Identification of novel regulators of hematopoietic stem cell development through refinement of stem cell localization and expression profiling. *Blood* **114**, 4645–4653. (doi:10.1182/blood-2009-06-230037)
122. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS. 2006 Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell* **124**, 407–421. (doi:10.1016/j.cell.2005.10.041)
123. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. 2008 Haematopoietic stem cell release is regulated by circadian oscillations. *Nature* **452**, 442–447. (doi:10.1038/nature06685)
124. Spiegel A *et al.* 2007 Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34⁺ cells through Wnt signaling. *Nat. Immunol.* **8**, 1123–1131. (doi:10.1038/ni1509)
125. Zovein AC *et al.* 2008 Fate tracing reveals the endothelial origin of hematopoietic stem cells. *Cell Stem Cell* **3**, 625–636. (doi:10.1016/j.stem.2008.09.018)
126. Jang IH *et al.* 2015 Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium. *Blood* **125**, 1418–1426. (doi:10.1182/blood-2014-04-568170)
127. Taoudi S, Medvinsky A. 2007 Functional identification of the hematopoietic stem cell niche in the ventral domain of the embryonic dorsal aorta. *Proc. Natl Acad. Sci. USA* **104**, 9399–9403. (doi:10.1073/pnas.0700984104)
128. Durand C, Robin C, Bollerot K, Baron MH, Ottersbach K, Dzierzak E. 2007 Embryonic stromal clones reveal developmental regulators of definitive hematopoietic stem cells. *Proc. Natl Acad. Sci. USA* **104**, 20 838–20 843. (doi:10.1073/pnas.0706923105)
129. Mascarenhas MI, Bacon WA, Kapeni C, Fitch SR, Kimber G, Cheng SW, Li J, Green AR, Ottersbach K. 2016 Analysis of Jak2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation. *Blood* **127**, 2298–2309. (doi:10.1182/blood-2015-08-664631)
130. McGarvey AC *et al.* 2017 A molecular roadmap of the AGM region reveals BMPER as a novel regulator of HSC maturation. *J. Exp. Med.* **214**, 3731–3751. (doi:10.1084/jem.20162012)
131. Mirshekar-Syahkal B *et al.* 2013 Dlk1 is a negative regulator of emerging hematopoietic stem and progenitor cells. *Haematologica* **98**, 163–171. (doi:10.3324/haematol.2012.070789)
132. Peeters M, Ottersbach K, Bollerot K, Orelio C, de Bruijn M, Wijgerde M, Dzierzak E. 2009 Ventral embryonic tissues and Hedgehog proteins induce early AGM hematopoietic stem cell development. *Development* **136**, 2613–2621. (doi:10.1242/dev.034728)
133. Souilhoul C *et al.* 2016 Inductive interactions mediated by interplay of asymmetric signalling underlie development of adult haematopoietic stem cells. *Nat. Commun.* **7**, 10784. (doi:10.1038/ncomms10784)
134. Mendes SC, Robin C, Dzierzak E. 2005 Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny. *Development* **132**, 1127–1136. (doi:10.1242/dev.01615)
135. Kumano K *et al.* 2003 Notch1 but not Notch2 is essential for generating hematopoietic stem cells from endothelial cells. *Immunity* **18**, 699–711. (doi:10.1016/S1074-7613(03)00117-1)